NEW YORK (
was one of several stocks trading near $5 poised to move on above-average volume Tuesday after the company said its endometriosis treatment met goals of a study.
said a Phase II Daisy PETAL study using its Gonadotropin-Releasing Hormone receptor antagonist, elagolix, showed "statistically significant and clinically meaningful top-line efficacy results." Piper Jaffray analysts upgraded the stock to overweight from neutral on the results.
Neurocrine Biosciences jumped by $1.32, or 48.4%, to $4.05 in the premarket session. The 50-day average daily volume for is 387,000, according to the
More on Biotech 14 Biotech Stocks Facing FDA Approval
slipped by 10 cents, or 2.1%, to $4.69 in the premarket session, one day after Goldman Sachs upgraded the wireless company to buy from neutral.
Goldman Sachs raised its price target on
to $6 from $3.50, citing improving churn metrics, which pushed Sprint shares higher by 8.6% Monday.The three-month average daily volume for Sprint is 63.49 million, according to Yahoo! Finance.
Several European bank stocks were trading sharply lower on continued debt fears. European Union officials warned Tuesday that Europe's economy would stagnate unless eurozone governments work on major reforms to boost growth.
Allied Irish Banks
dropped 12.8% to $2.19 in Tuesday's premarket session,
Bank of Ireland
lost 12.2% to $4.45,
Lloyds Banking Group
slid 7.3% to $2.93, and
National Bank of Greece
fell 6.1% to $2.47.
-- Written by Robert Holmes in Boston
Follow Robert Holmes on
and become a fan of TheStreet.com on